What share options did NSRX Interim CFO Elmaliah Oren report?

Elmaliah Oren reported two direct option positions: 24,680 options outstanding and fully vested and exercisable, and a separate grant of 27,460 options, of which 13,840 were vested and exercisable as of September 18, 2026.

Nasus Pharma interim CFO reports 52K options

As of September 18, 2026, 24,680 options were fully vested and exercisable, while 13,840 of another 27,460-option grant were vested.

Available on EDGAR 09/23/2026 - 06:15 AM EDT Accepted by SEC EDGAR 09/23/2026 - 06:14 AM EDT

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Nasus Pharma Ltd (NSRX) Interim CFO Elmaliah Oren reported two direct share-option positions. As of September 18, 2026, 24,680 options were outstanding, fully vested and exercisable at $1.2264 per share, expiring November 28, 2029. A January 17, 2025 grant covered 27,460 options, of which 13,840 were vested and exercisable as of September 18, 2026, at $6.0462 per share, expiring January 17, 2035.

Insider Trade Summary

Holdings reported, no transactions

Holdings

Insider Elmaliah Oren

Role Interim CFO

Type	Security	Shares	Price	Value
Holding	Share options (right to buy) ^F1	--	--	--
Holding	Share options (right to buy) ^F2	--	--	--

Holdings: Share options (right to buy) — 52,140 contracts (Direct)

Footnotes (2)

F1. Options to purchase 24,680 ordinary shares of the Issuer, no par value ("Ordinary Shares") were granted on November 28, 2019. As of September 18, 2026, 24,680 options remain outstanding, all of which are vested and exercisable, at an exercise price of $1.2264 per share, expiring November 28, 2029.
F2. Options to purchase 27,460 Ordinary Shares were granted on January 17, 2025, with the total grant vesting in equal quarterly installments of 8.33% commencing on January 17, 2025. As of September 18, 2026, 13,840 are vested and exercisable, at an exercise price of $6.0462 per share, expiring January 17, 2035.

Key Figures

Options outstanding: 24,680 options Options granted: 27,460 options Options vested and exercisable: 13,840 options +4 more

7 metrics

Options outstanding 24,680 options As of September 18, 2026; fully vested and exercisable

Options granted 27,460 options Grant dated January 17, 2025

Options vested and exercisable 13,840 options Of the January 17, 2025 grant, as of September 18, 2026

Exercise price $1.2264 per share 24,680 options expiring November 28, 2029

Exercise price $6.0462 per share 27,460-option grant expiring January 17, 2035

Expiration date November 28, 2029 24,680 options

Expiration date January 17, 2035 27,460-option grant

Key Terms

vested and exercisable, exercise price, equal quarterly installments

3 terms

vested and exercisable financial

"all of which are vested and exercisable"

exercise price financial

"at an exercise price of $1.2264 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

equal quarterly installments financial

"vesting in equal quarterly installments of 8.33%"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many of Elmaliah Oren's NSRX options were vested as of September 18, 2026?

The 24,680 options granted in 2019 were all vested and exercisable. Of the 27,460 options granted in 2025, 13,840 were vested and exercisable.

What are the exercise prices for the NSRX options?

The 24,680 options have an exercise price of $1.2264 per share. The 27,460-option grant has an exercise price of $6.0462 per share.

When do the reported NSRX options expire?

The 24,680 options expire November 28, 2029. The 27,460-option grant expires January 17, 2035.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Elmaliah Oren

(Last)

(First)

(Middle)

P.O. BOX 284

(Street)

TEL-AVIV-YAFO

6100201

(City)

(State)

(Zip)

ISRAEL

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
09/19/2026

3. Issuer Name and Ticker or Trading Symbol
Nasus Pharma Ltd [ NSRX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Interim CFO

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Share options (right to buy)⁽¹⁾	06/13/2020	11/28/2029	Ordinary Shares	24,680	$1.2264	D
Share options (right to buy)⁽²⁾	01/17/2025	01/17/2035	Ordinary Shares	27,460	$6.0462	D

Explanation of Responses:

1. Options to purchase 24,680 ordinary shares of the Issuer, no par value ("Ordinary Shares") were granted on November 28, 2019. As of September 18, 2026, 24,680 options remain outstanding, all of which are vested and exercisable, at an exercise price of $1.2264 per share, expiring November 28, 2029.

2. Options to purchase 27,460 Ordinary Shares were granted on January 17, 2025, with the total grant vesting in equal quarterly installments of 8.33% commencing on January 17, 2025. As of September 18, 2026, 13,840 are vested and exercisable, at an exercise price of $6.0462 per share, expiring January 17, 2035.

	/s/ Oren Elmaliah	09/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR